Updated

A newly FDA-cleared PTSD treatment using personalized brain mapping and magnetic stimulation to target abnormal brain activity reported a 52% reduction in symptoms and 68% remission in a clinical trial published October 23, 2026. Researchers believe the technology could transform mental health care by enabling more precise treatments for PTSD and potentially other psychiatric conditions.